ArticleJournal of thoracic disease2024
A novel minimally invasive surgical technique (LONG procedure) for treating chylopericardium.
Article in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chylopericardium is a rare disease resulting from lymphatic system dysfunction and characterized by recurrent chylous pericardial effusion and cardiac compression. Traditional treatments like fasting, somatostatin injection and ligation of pericardial lymphatic vessels are less effective, with high recurrence rate. Fenestration is regarded as the last resort for treating chylopericardium. Our team designed a novel minimally invasive pericardial fenestration surgical technique (LONG procedure) for the treatment of chylopericardium. This study assessed its efficacy and technical characteristics, with the aim of providing valuable insights into the surgical treatment and management of chylopericardium. Methods: The clinical data of 7 patients with chylopericardium treated by the LONG procedure in the lymphatic surgery department from January 2018 to June 2024 were retrospectively analyzed. The data included the patients' medical history, imaging examination, pericardial effusion analysis, operative details, drainage output, length of hospital stay, and follow-up results. The indicators were analyzed to assess the technical characteristics of the LONG procedure. Results: Seven male patients aged between 7 and 35 years were enrolled in this study. The duration of the disease course ranged from 3 months to 10 years. All patients had previously accepted pericardial drainage, a fat-free diet, and anti-infection treatments. Some patients had also undergone thoracic duct adhesiolysis, embolization, or lymphatic ligation; however, they experienced recurrent pericardial effusion. Upon admission, all patients presented with at least moderate volumes of pericardial effusion. The LONG procedure was successfully performed on all patients, with an operation time of 54 to 95 minutes and minimal intraoperative blood loss (1-5 mL). Chest tubes were removed once the drainage became clear, typically between 15 to 37 days postoperation. Patients were discharged after 1-2 weeks of observation, with no recurrence or complications observed during the follow-up period of up to 5 years. Conclusions: The LONG procedure seems to be effective for the treatment of chylopericardium with low postoperative recurrence rates, but more research and long-term observation are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.